Reuters logo
BRIEF-Medicines Co, Alnylam Pharma announce agreement with FDA on phase III clinical program for inclisiran
2017年4月26日 / 上午11点28分 / 5 个月前

BRIEF-Medicines Co, Alnylam Pharma announce agreement with FDA on phase III clinical program for inclisiran

April 26 (Reuters) - Medicines Co

* The medicines company and alnylam pharmaceuticals announce agreement with fda on phase iii clinical program for inclisiran

* Medicines co- nda submission anticipated at or around end of 2019

* Medicines co- company has received final, end-of-phase ii meeting minutes from fda Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below